Abstract: Objective To study the effect of the novel hemoperfusion apparatus on removing protein-bound toxins, such as advanced glycation end products (AGEs) and indoxyl sulfate (IS).Methods Eighty-eight patients undergoing maintenance hemodialysis (HD) from The Foshan First People's Hospital and Shanghai Changzhen Hospital were randomly divided into two groups. Patients in group A received HA130 (the commonly used perfusion apparatus) HP+HD, followed by the combined MG150 HP+HD treatment once, and those in group B were first treated with MG150 HP+HD and then received the HA130 HP+HD treatment. The serum AGEs, IS and β₂-microglobulin were detected before and after treatment. The effectiveness and safety of the MG150 apparatus on removing protein-bound toxins were observed.Results Forty-four patients were included in each hospital. There was no significant difference in sex, age, body weight, blood pressure, Kt/V, serum levels of hemoglobin, albumin, β₂-microglobulin (β₂-MG), IS and tumor necrosis factor-α (TNF-α), except AGEs (285.77±107.03 vs. 456.89±129.10 ng/L, P<0.01) and C-reactive protein (CRP) (2.67±2.58 vs. 6.38±8.83 mg/L, P<0.01) between the two groups at the beginning of the treatment. Patients treated with HP+HD had higher levels of AGEs and IS. Meanwhile, patients treated with the combined HP+HD with the MG150 apparatus exhibited significantly lower levels of serum AGEs and IS than HA130. There were 7 cases of slight adverse events.Conclusions The novel hemoperfusion apparatus MG150 combined with HD can effectively remove the protein-bound uremic toxins, and it is deserved to be promoted and used clinically.